title: The G-protein coupled chemoattractant receptor FPR2 promotes malignant phenotype of human colon cancer cells.
abstract: The G-protein coupled chemoattractant receptor formylpeptide receptor-2 (FPR2 in human, Fpr2 in mice) is expressed by mouse colon epithelial cells and plays a critical role in mediating mucosal homeostasis and inflammatory responses. However, the biological role of FPR2 in human colon is unclear. Our investigation revealed that a considerable number of human colon cancer cell lines expressed FPR2 and its ligands promoted cell migration and proliferation. Human colon cancer cell lines expressing high levels of FPR2 also formed more rapidly growing tumors in immunocompromised mice as compared with cell lines expressing lower levels of FPR2. Knocking down of FPR2 from colon cancer cell lines highly expressing FPR2 reduced their tumorigenicity. Clinically, FPR2 is more highly expressed in progressive colon cancer, associated with poorer patient prognosis. These results suggest that FPR2 can be high-jacked by colon cancer cells for their growth advantage, thus becoming a potential target for therapeutic development.
authors.affiliation: Department of Pulmonary Medicine, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong UniversityShanghai 200025, China; Cancer and Inflammation Program, Center for Cancer Research, National Cancer InstituteFrederick, MD 21702, USA.
authors.forename: Yi
authors.initials: Y
authors.lastname: Xiang
authors.affiliation: Institute of Pathology and Southwest Cancer Center, Third Military Medical University Chongqing 400038, China.
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Yao
authors.affiliation: Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute Frederick, MD 21702, USA.
authors.forename: Keqiang
authors.initials: K
authors.lastname: Chen
authors.affiliation: Department of Pulmonary Medicine, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong UniversityShanghai 200025, China; Cancer and Inflammation Program, Center for Cancer Research, National Cancer InstituteFrederick, MD 21702, USA.
authors.forename: Xiafei
authors.initials: X
authors.lastname: Wang
authors.affiliation: Cancer and Inflammation Program, Center for Cancer Research, National Cancer InstituteFrederick, MD 21702, USA; Department of Liver Surgery, Shanghai Cancer Center, Fudan UniversityShanghai 200032, China.
authors.forename: Jiamin
authors.initials: J
authors.lastname: Zhou
authors.affiliation: Basic Research Program, Leidos Biomedical Research, Inc. Frederick, MD 21702, USA.
authors.forename: Wanghua
authors.initials: W
authors.lastname: Gong
authors.affiliation: Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute Frederick, MD 21702, USA.
authors.forename: Teizo
authors.initials: T
authors.lastname: Yoshimura
authors.affiliation: College of Life Sciences and Bioengineering, School of Sciences, Beijing Jiaotong University Beijing 100044, China.
authors.forename: Jiaqiang
authors.initials: J
authors.lastname: Huang
authors.affiliation: Department of Gastroenterology, Southwest Hospital, Third Military Medical University Chongqing 400038, China.
authors.forename: Rongquan
authors.initials: R
authors.lastname: Wang
authors.affiliation: Institute of Immunology, Third Military Medical University Chongqing 400038, China.
authors.forename: Yuzhang
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Department of Pulmonary Medicine, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai 200025, China.
authors.forename: Guochao
authors.initials: G
authors.lastname: Shi
authors.affiliation: Institute of Pathology and Southwest Cancer Center, Third Military Medical University Chongqing 400038, China.
authors.forename: Xiuwu
authors.initials: X
authors.lastname: Bian
authors.affiliation: Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute Frederick, MD 21702, USA.
authors.forename: Jiming
authors.initials: J
authors.lastname: Wang
keywords: Colon; FPR2; cancer; prognosis; tumorigenesis